Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

Todd L. Rosenblat, Michael R. McDevitt, Deborah A. Mulford, Neeta Pandit-Taskar, Chaitanya R. Divgi, Katherine S. Panageas, Mark L. Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences